2026 年第 1 期 第 21 卷

头孢哌酮钠舒巴坦钠联合乌司他丁治疗肾移植并发重症肺炎患者的有效性及安全性分析

Efficacy and safety analysis of cefoperazone sodium/sulbactam sodium combined with ulinastatin in the treatment of renal transplant recipients with severe pneumonia

作者：佟嫱1鞠思薇2曾茜1原苑1

英文作者：Tong Qiang1 Ju Siwei2 Zeng Xi1 Yuan Yuan1

单位：1北部战区总医院临床药学科，沈阳110016；2沈阳药科大学生命科学与生物制药学院，沈阳110016

英文单位：1Department of Clinical Pharmacy General Hospital of Northern Theater Command Shenyang 110016 China; 2School of Life Sciences and Biopharmaceuticals Shenyang Pharmaceutical University Shenyang 110016 China

关键词：肾移植；重症肺炎；头孢哌酮钠舒巴坦钠；乌司他丁；有效性；安全性

英文关键词：Renaltransplantation;Severepneumonia;Cefoperazonesodium/sulbactamsodium;Ulinastatin;Efficacy;Safety

• 摘要：

• 目的 评估头孢哌酮钠舒巴坦钠(CPZ-SBT)联合乌司他丁治疗肾移植并发重症肺炎(RTSP)患者的有效性及安全性。方法 回顾性分析2022年1月至2025年5月北部战区总医院收治的74例RTSP患者的临床资料。根据治疗方式将其分为对照组(给予CPZ-SBT治疗)与联合组(给予CPZ-SBT联合乌司他丁治疗)，各37例。2组RTSP患者均连续治疗7 d以上，记录并比较2组临床疗效，治疗前后临床指标、呼吸功能指标、炎症因子指标及治疗期间不良反应。结果 2组患者对CPZ-SBT治疗均敏感，联合组总有效率略高于对照组［97.3%(36/37)比89.2%(33/37)］，但差异无统计学意义(P=0.165)。联合组体温恢复时间、喘息消失时间、咳嗽消失时间均短于对照组(均P<0.05)。治疗后，2组动脉血氧饱和度、动脉血氧分压均高于治疗前且联合组高于对照组，动脉血二氧化碳分压、降钙素原、C反应蛋白水平均低于治疗前且联合组低于对照组(均P<0.05)。联合组不良反应总发生率略高于对照组［10.8%(4/37)比5.4%(2/37)］，但差异无统计学意义(P=0.394)。结论 对RTSP患者给予CPZ-SBT联合乌司他丁治疗可以有效促进患者症状恢复，改善呼吸功能及调节炎症因子指标水平，且不良反应较为轻微，安全有效。 

• Objective To evaluate the efficacy and safety of cefoperazone sodium/sulbactam sodium (CPZ-SBT) combined with ulinastatin in the treatment of renal transplant recipients with severe pneumonia (RTSP). Methods A retrospective analysis was performed on the clinical data of 74 RTSP patients admitted to General Hospital of Northern Theater Command of the Chinese People′s Liberation Army from January 2022 to May 2025. The patients were divided into control group (treated with CPZ-SBT) and combination group (treated with CPZ-SBT combined with ulinastatin) according to the treatment regimen, with 37 cases in each group. Both groups received continuous treatment for more than 7 d. The clinical efficacy, clinical indicators, respiratory function indicators, inflammatory factor levels before and after treatment, and adverse reactions during treatment were recorded and compared between the two groups. Results Both groups were sensitive to CPZ-SBT treatment. The total effective rate of the combination group was slightly higher than that of the control group ［97.3%(36/37) vs 89.2%(33/37)］, but the difference was not statistically significant (P=0.165). The time to body temperature recovery, wheezing resolution, and cough resolution in the combination group were significantly shorter than those in the control group (all P<0.05). After treatment, the arterial oxygen saturation and arterial partial pressure of oxygen in both groups were significantly higher than those before treatment, with the combination group showing higher values than the control group. The arterial partial pressure of carbon dioxide, procalcitonin, and C-reactive protein levels in both groups were significantly lower than those before treatment, and the combination group had lower levels than the control group (all P<0.05). The total incidence of adverse reactions in the combination group was slightly higher than that in the control group ［10.8%(4/37) vs 5.4%(2/37)］, but the difference was not statistically significant (P=0.394). Conclusion  CPZ-SBT combined with ulinastatin in the treatment of RTSP patients can effectively promote symptom recovery, improve respiratory function, and regulate inflammatory factor levels, with mild adverse reactions, showing good safety and efficacy.